Merck + Co., Inc.

Robert M Purick

David Askin

Richard John Varsolona

R Scott Hoerrner

Ralph P Volante

Zhijian Lu

Yuan Cheng

Paul J Reider

Kevin Tyler Chapman

James R Tata

Subharekha Raghavan

Joseph Leslie Duffy

Nancy J Kevin

Fengqi Zhang

Thomas A Rano

Joseph D Armstrong, Iii

Brian Anthony Kirk

Fred Fleitz

Daniel E Petrillo

Tracy Huening

&ggr;-Hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamide compounds are inhibitors of HIV protease and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described. These compounds are effective against HIV viral mutants which are resistant to HIV protease inhibitors currently used for treating AIDS and HIV infection.

Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides and uses thereof

This invention relates to a sulfate salt of an HIV protease inhibitor, Compound A, of formula: ##STR1## Compound A is useful in the treatment of AIDS, ARC or HIV infection in adults and children. Processes for making the sulfate salt of Compound A are also disclosed.

HIV protease inhibitor

Growing community of inventors

Edison, NJ, United States of America

Robert M Purick